



BLUE JET HEALTHCARE LIMITED

REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA,
PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705

T : 022- 41840550 / 40037603

F : +91 22 27814204

E : sales@bluejethealthcare.com

CIN NO. : L99999MH1968PLC014154

January 29, 2025

To,

BSE Limited Phiroze Jeejebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	National Stock Exchange of India Limited “Exchange Plaza” Bandra-Kurla Complex, Bandra (East) Mumbai – 400051 Symbol: BLUEJET
---	---

ISIN : INEOKBH01020

Subject: Press Release – Blue Jet Healthcare, Q3Y 25 for Quarter and Nine months ended December 31st 2024 Unaudited Financial Results.

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release issued by Blue Jet Healthcare Limited.

Kindly take the same in your records.

We request you to take the same on your record.

Thanking you,

Yours faithfully,

For **Blue Jet Healthcare Limited**

SWETA Digitally signed by
SWETA PODDAR
Date: 2025.01.29
16:27:28 +05'30'
PODDAR

Ms. Sweta Poddar
Company Secretary & Compliance Officer
(M. No.: F12287)

Unit I

3/2, Milestone, Kalyan Nurbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, **Tel.:** 91 251 2280283 **Fax:** +91 251 2280567

Unit II

Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambarnath (W) 421501. **Tel.:** +91 8956363877/8956363878

Unit III

K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, **Tel.:** + 91 22 2207 5307/ 6192 /1691 **Fax:** +91 22 2207 0294

Email : info@bluejethealthcare.com / **Website :** www.bluejethealthcare.com

Blue Jet Healthcare Announces Q3 & 9M FY25 Results

Highest Ever PAT recorded at Rs. 990 mn

Revenue at Rs. 3,184 mn; a jump of 90.9% YoY

EBITDA Margins Climb to 39%; up by 630bps

Mumbai, January 29, 2025: Blue Jet Healthcare Limited (BLUEJET) (BSE: 544009, NSE: BLUEJET) reported financial results for the quarter and nine month ended December 31, 2024, on 29th January 2025.

Financial Results – Q3 & 9M FY25

Particulars (Rs. Mn)	Q3FY25	Q3FY24	YoY	Q2FY25	QoQ	9MFY25	9MFY24	YoY
Revenue from Operations	3,184	1,668	90.9%	2,083	52.9%	6,895	5,277	30.7%
EBITDA	1,240	546	127.2%	695	78.5%	2,378	1,762	35.0%
EBITDA Margin	39.0%	32.7%	630 bps	33.4%	560 bps	34.5%	33.4%	110 bps
Exceptional items (*)	0	(97)		0		0	(97)	
PAT	990	321	208.3%	583	69.6%	1,951	1,241	57.2%
PAT Margin	31.1	19.3%	1,180 bps	28.0%	311 bps	28.3%	23.5%	480 bps

() The loss of damaged assets and compensation to employees aggregating has been accounted as an exceptional item for the quarter due to Fire incident at one of the facility*

Commenting on results, Mr. Shiven Arora, Managing Director, Blue Jet Healthcare Limited, said: *“Blue Jet witnessed a remarkable quarter delivering strong performance as we clocked a revenue of Rs. 3,184 mn, giving a 91% YoY growth as compared to the same quarter last year. PAT for the quarter came at Rs. 990 mn with a growth of 208% on a YoY basis. The EBITDA margin came at 39%, showcasing our efforts to strengthen our financial foundation and operational efficiencies. This success was largely driven by the Pharmaceutical Intermediate business and the High Intensity Sweetener business.*

We commissioned one manufacturing block at Ambernath in the quarter, a significant milestone for us which will help us reap benefits in the coming quarters. Even Amidst ongoing industry challenges, we are poised for quality growth in FY25. “

Key Results Highlights:

Q3 FY25:

- ✓ **Revenue from operations** for Q3 FY25 stood at **Rs. 3,184 mn** which grew **52.9% QoQ** compared to **Rs. 2,083 mn** in Q2 FY25; **up 90.9%** on YoY basis compared to **Rs. 1,668 mn** in Q3 FY24.
- ✓ **Revenue growth** is mainly driven by higher sales in Pharmaceutical Intermediates in Q3 FY25, and **improved profitability** was mainly due to high sales volume, cost optimization leading to absorption of fixed cost.

- ✓ EBITDA for the quarter came at **Rs. 1,240 mn**, which was **up 78.5% QoQ** compared to **Rs. 695 mn** in **Q2 FY25**; **up 127.2% YoY** compared to **Rs. 546 mn** in **Q3 FY24**.
- ✓ EBITDA margin for the quarter came at **39.0%** as compared to **33.4%** in **Q2 FY25** **up 559 bps QoQ**; **32.7%** in **Q3 FY24**, **up 622 bps YoY**.
- ✓ **Company posted highest ever PAT** for the quarter was at **Rs. 990 mn**, which **grew 69.6% QoQ** compared to **Rs. 583 mn**; **up 208.3% YoY** compared to **Rs. 321 mn** in **Q3 FY24**.
- ✓ PAT margin for the quarter came at **31.1%** as compared to **28.0%** in **Q2 FY25**, **up 307 bps QoQ**; **19.3%** in **Q3 FY24**, **up 1,183 bps**.

9M FY25:

- ✓ Revenue from operations for 9M FY25 stood at **Rs. 6,895 mn** compared to **Rs. 5,277 mn** in **9M FY24**, **up 30.7% YoY**
- ✓ EBITDA for 9M FY25 came at **Rs. 2,378 mn** **up 35% YoY** compared to **Rs. 1,762 mn** in **9M FY24**.
- ✓ EBITDA margin for 9M FY25 was at **34.5%** as compared to **33.4%** in **9M FY24**, **down 110 bps YoY**.
- ✓ PAT for 9M FY25 stands at **Rs. 1,951 mn** **up 57.2% YoY** compared to **Rs. 1,241 mn** in **9M FY24**.
- ✓ PAT margin for 9M FY25 was at **28.3%** as compared to **23.5%** in **9M FY24**, **up 478 bps YoY**.
- ✓ **Robust Liquidity** with Cash & Cash equivalent and Treasury Investments stands at **Rs 3,313 Mn** as on 31st December 2024.

Other Highlights:

- ✓ **Company commissioned additional manufacturing block** during Q3 FY25 at **Ambarnath** for manufacturing **Advance Contrast Media** with investment around **Rs. 100 mn**.
- ✓ **Company expects** advanced contrast media dispatched to happen in **Q4 FY25**
- ✓ **Company** have planned to set up a state of Art **Research & Development** Centre with an Investment of upto **Rs 40 crs**
- ✓

ABOUT BLUE JET HEALTHCARE LIMITED:

Blue Jet Healthcare Ltd a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization (“CDMO”) business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners. They have built a long-term customer base with innovator and multi-national generic pharmaceutical companies,

supported by multi-year contracts. They supply a critical starting intermediate and several advanced intermediates to three of the largest contrast media manufacturers in the world, including GE Healthcare, Guerbet, and Bracco. They also supply high-intensity sweeteners to several multi-national companies, including Colgate Palmolive (India) Limited and Unilever.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and BLUEJET has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

<p>Investor Relations at Blue Jet Healthcare Limited Sanjay Sinha, Deputy Chief Financial Officer sanjay.sinha@bluejethealthcare.com</p> <p>Ernst & Young Kunal Bhoite kunal.bhoite@in.ey.com</p> <p>Advait Bhadekar Advait.bhadekar@in.ey.com</p>	<p>Registered Office 701,702, 7th Floor, Bhumiraj Costarica, Sector 18, Sanpada, Navi Mumbai Thane 400705, Maharashtra, India CIN: U99999MH1968PLC014154 ISIN: INE0KBH01020 NSE Code: BLUEJET BSE CODE: 544009 Website: www.bluejethealthcare.com</p>
---	---